Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 461 to 470 of 864 total matches.

A Once-Yearly IV Bisphosphonate for Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2007  (Issue 1273)
University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
Zoledronic acid (Reclast - Novartis) is the first bisphosphonate approved by the FDA for once-yearly intravenous (IV) treatment of osteoporosis in postmenopausal women. Reclast is also approved for treatment of Paget's disease. Another IV formulation of zoledronic acid (Zometa) is approved for treatment of hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors.
Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90 |  Show IntroductionHide Introduction

Doripenem (Doribax) - A New Parenteral Carbapenem

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008  (Issue 1278)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Doripenem (Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.
Med Lett Drugs Ther. 2008 Jan 28;50(1278):5-7 |  Show IntroductionHide Introduction

Prevention of Venous Thromboembolism in Orthopedic Surgery

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Major orthopedic surgery creates a prothrombotic state by causing tissue injury during the operation and requiring relative immobilization during recovery. Without thromboprophylaxis, 40-60% of patients undergoing major knee or hip surgery develop venographically detectable deep vein thrombosis (DVT) and 1 in 300 undergoing total hip replacement will have a symptomatic pulmonary embolism (PE). Thromboprophylaxis reduces the incidence of venous thromboembolism (VTE), but it also can cause bleeding. New guidelines for prevention of VTE have recently been published.
Med Lett Drugs Ther. 2008 Nov 3;50(1298):86-8 |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Propafenone for Cardiac Arrhythmia

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 1990  (Issue 816)
tolerated than disopyramide (Norpace; and others) (F Naccarella et al, Am Heart J, 109:833, 1985; T Jonason ...
Propafenone (Rythmol - Knoll), a class IC antiarrhythmic drug used in Europe for treatment of various arrhythmias for more than 10 years, was recently marketed in the USA for oral treatment of life-threatening ventricular arrhythmias such as sustained ventricular tachycardia. This restrictive labeling reflects concerns arising from the interim report of the Cardiac Arrhythmia Suppression Trial, in which post-myocardial infarction patients with asymptomatic or mildly symptomatic ventricular arrhythmias treated with the class IC antiarrhythmic drugs encainide (Enkaid) or flecainide...
Med Lett Drugs Ther. 1990 Apr 20;32(816):37-8 |  Show IntroductionHide Introduction

Rifabutin

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993  (Issue 895)
Pneumocystis carinii pneumonia (PCP) (F Gordin et al, Int Conf AIDS, 8:B100, 1992; W Cameron et al, Int Conf ...
Rifabutin (formerly ansamycin; Mycobutin - Adria), a rifamycin antibiotic similar to rifampin (Rifadin, Rimactane) was recently approved by the US Food and Drug Administration for prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
Med Lett Drugs Ther. 1993 Apr 30;35(895):36-8 |  Show IntroductionHide Introduction

Doxepin Cream for Pruritus

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 1994  (Issue 934)
results (C-F Wahlgren et al, Br J Dermatol, 122:545, 1990; EW Monroe, Clin Ther, 14:17, 1992; M La Rosa ...
The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream (Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic antidepressant (Sinequan, and others).
Med Lett Drugs Ther. 1994 Oct 28;36(934):99-100 |  Show IntroductionHide Introduction

Dexfenfluramine for Obesity

   
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996  (Issue 979)
pulmonary hypertension (PPH), which is often fatal, had used either d,l-fenfluramine or dexfenfluramine (F ...
Dexfenfluramine (Redux - Wyeth-Ayerst) has been approved by the US Food and Drug Administration as an aid to diet for treatment of obesity and maintenance of weight loss. Dexfenfluramine is the dextrorotatory isomer of d,l-fenfluramine (Pondimin), which has been marketed for short-term weight reduction for many years and recently has been widely used in combination with phentermine (Ionamin, and others), a sympathomimetic drug (Medical Letter, 36:107, 1994).
Med Lett Drugs Ther. 1996 Jul 19;38(979):64-5 |  Show IntroductionHide Introduction

New Monoclonal Antibodies to Prevent Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998  (Issue 1036)
% with daclizumab and 90% with placebo (F Vincenti et al, N Engl J Med, 338:161, 1998). A similar trial in 275 ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Med Lett Drugs Ther. 1998 Sep 25;40(1036):93-4 |  Show IntroductionHide Introduction

Plan B: A Progestin-Only Emergency Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2000  (Issue 1070)
, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL ...
The FDA has approved marketing of Plan B (Women's Capital Corporation), an emergency contraceptive "pill pack"that contains two 0.75-mg tablets of levonorgestrel.
Med Lett Drugs Ther. 2000 Jan 24;42(1070):10 |  Show IntroductionHide Introduction